Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234
Michikawa C, Torres-Saavedra P, Silver N, Harari P, Kies M, Rosenthal D, Le Q, Jordan R, Duose D, Mallampati S, Trivedi S, Luthra R, Wistuba I, Osman A, Lichtarge O, Foote R, Parvathaneni U, Hayes D, Pickering C, Myers J. Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Advances In Radiation Oncology 2022, 7: 100989. PMID: 36420184, PMCID: PMC9677209, DOI: 10.1016/j.adro.2022.100989.Peer-Reviewed Original ResearchDisease-free survivalCisplatin armDocetaxel armOverall survivalPrognostic markerRadiation therapyHigh-risk pathologic featuresHuman papillomavirus-negative headPhase 2 clinical trialPhase 2 studyBetter overall survivalLow-risk groupReliable prognostic markersEvolutionary action scoreAdvanced HNSCCAdjuvant treatmentResection samplesClinical outcomesDistant metastasisPathologic featuresPoor outcomeNeck cancerClinical trialsTreatment outcomesBetter survival